Penn Highlands Dubois
DuBois, Pennsylvania, 15801, United States
NCT Number: NCT06340932
This is a prospective, quasi-experimental, cohort study comparing patients treated with one of two postoperative pain management protocols. The two protocols assessed will be the current standard of care protocol for Anterior Cruciate Ligament Reconstruction (ACLR) postoperative pain control utilized by Dr. Matthew Varacallo and then an opioid avoidance protocol that is planned to be implemented on the Spring of 2024. The study is voluntary, however all patients will be treated with either of the two protocols depending on their date of surgery. This study will include patients aged 15 years and older who consent to the participation in the study. Patients will be identified utilizing the operative surgeon's appointment calendar and will be screened and offered inclusion in the study if applicable at their pre-operative visit. Data will be collected via patient medication and pain diary, phone call, and clinician administration of standardized outcome questionnaires. Patients will be included in the standard of care group if ACLR is performed prior to the change in protocol in the Spring of 2024 or the opioid avoidance group if performed after the protocol change.
The primary objective of this study is to evaluate the effect of the opioid avoidance protocol on opioid use in milligrams of morphine equivalent (MME) from postoperative day (POD) 0 to 7 after ACLR compared to the current standard of care pain management protocol.
Secondary objectives are to:
* evaluate the effects of an opioid avoidance protocol on the daily average numeric rating scale (NRS) pain scores from POD0-7 * evaluate the effects of an opioid avoidance protocol on the daily worst NRS pain score from POD0-7 * evaluate the ability to recover opioid free through 7, 30, and 60 days * evaluate the quality of recovery 15 (QoR-15) scores on POD2 * assess the number of opioid prescriptions required by patients in the 60 day recover period * assess Knee Injury and Osteoarthritis Outcome Score (KOOS) pain and symptom scales at 8 weeks post-operatively between groups.
Looking for future studies?
Notify Me15 year and older
All sexes
Observational
DuBois, Pennsylvania, 15801, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
i. Female subjects must have a confirmatory negative pregnancy test as part of the routine pre-operative laboratory testing ii. Subjects must endorse a plan to utilize contraceptives (condoms, hormonal birth control, IUD, etc.) for any sexual activity during the study period.
Exclusion criteria
i. Cryoglobulinemia (presence of abnormal proteins in the blood that thicken in cold temperatures) ii. Paroxysmal cold hemoglobinuria (an autoimmune disorder where cold-reacting antibodies that attack and destroy red blood cells) iii. Cold urticaria (temporary itchy welts [hives] on skin exposed to cold temperatures) iv. Raynaud's disease (which causes some areas of the body, such as fingers and toes, to feel numb and cold in response to cold temperatures) v. Open and/or infected wounds at or near the study treatment site vi. Coagulopathy (problems with blood clotting)
i. Mood disorder (for example, major depression, bipolar) ii. Psychotic disorder (for example, schizophrenia)
i. Alcohol abuse or dependence ii. Illicit drug use iii. Opioid abuse or dependence (greater than or equal to 40 mg morphine equivalent dose by mouth per day in the past 30 days)
Cryoneurolysis of 5 sensory nerves (Intermediate branch of the AFCN, Medial Femoral Cutaneous Nerve, Suprapatellar branch of the saphenous nerve, 2 branches of the infrapatellar branch of the saphenous nerve) causing Wallerian degeneration
200mg BID
Other names: Celebrex
1000mg q8h
Other names: Tylenol
As needed
As needed
20mL of 0.25% bupivacaine HCl adductor canal block and 15mL of 0.25% bupivacaine HCl (+/- 5mL of normal saline) iPACK
500mg q6h prn
Time frame: 7 days
Total use of opioids in milligrams of morphine equivalent from day 0 through day 7
Time frame: 7 Days
Average daily pain each day from POD0-7
Time frame: 7 days
Average of highest pain scores daily
Time frame: Week 8
Pain subscale of the KOOS questionnaire
Time frame: Day 2
QoR15 score on POD2
Time frame: 8 weeks
Ability to participate in physical therapy weekly
Time frame: Week 8
Symptom subscale of the KOOS questionnaire
Time frame: Day 30 and Day 60
Number of opioid prescriptions filled by patient at day 30 and 60
Time frame: Days 7, 30, and 60
Percentage of patients who did not utilize opioid prescriptions at 3 time points
Matthew Varacallo
Other
Impact of Opioid Avoidance Protocol for ACL Reconstruction Surgery
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07723625
ACL Injury, ACL Tear
Denpasar, Bali, Indonesia
View Trial DetailsNCT07681193
ACL Injury, ACL Tear
Chapel Hill, North Carolina, United States
View Trial DetailsNCT05876013
ACL, ACL Injury
Trondheim, Trøndelag, Norway
View Trial DetailsNCT04484961
ACL Tear, Anterior Cruciate Ligament Injuries
View Trial Details